Coherus Oncology (CHRS) Stock: Buy, Sell, or Hold?
CHRS - Coherus Oncology, Inc. Common Stock
$1.16
0.00 (0.00%)
▲
5d:
+2.65%
30d:
-18.31%
90d:
-25.64%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
30d
Get Alerted When CHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CHRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CHRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CHRS is currently trading at $1.16, which is considered oversold relative to its 30-day fair value range of $1.21 to $1.41.
Technical Outlook: Technically, CHRS is in a strong uptrend. Immediate support is located at $1.10, while resistance sits at $1.43.
Market Sentiment: CHRS scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.75 (+568.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CHRS is in a strong uptrend. Immediate support is located at $1.10, while resistance sits at $1.43.
Market Sentiment: CHRS scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.75 (+568.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.21 -
$1.41
Company Quality Score
69/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (73/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 568.1% below Wall St target ($7.75)
- CAUTION: Bottoming setup, but lagging the sector by 29% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$1.21 -
$1.41
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.10
Resistance Level
$1.43
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.84
Wall Street Target
$7.75
(+568.1%)
Revenue Growth (YoY)
39.5%
Earnings Growth (YoY)
-75.5%
Profit Margin
-259.4%
Share & Embed Analysis
Last updated: October 05, 2026 7:35 AM ET
Data refreshes hourly during market hours. Next update: 8:35 AM
Data refreshes hourly during market hours. Next update: 8:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$294 | 67 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
19 analysts |
$644 | 67 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
27 analysts |
$853 | 48 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$32 | 62 BUY |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
13 analysts |
$74 | 66 BUY |
